3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
62
Myelodysplastic Syndromes
33
Leukemia, Myelomonocytic, Chronic
16
Leukemia
16
Recurrence
9
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Myelomonocytic, Acute
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia, Monocytic, Acute
5
Hodgkin Disease
5
Myeloproliferative Disorders
4
Congenital Abnormalities
4
Anemia, Refractory, with Excess of Blasts
4
Thrombocythemia, Essential
3
Primary Myelofibrosis
3
Polycythemia Vera
3
Lymphoma
3
Blast Crisis
3
Triple Negative Breast Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasm, Residual
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Congenital Bone Marrow Failure Syndromes
×
Decitabine
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled